Sanofi Ventures Research
Investment Thesis
Sanofi Ventures is the corporate venture capital arm of Sanofi, functioning as the pharmaceutical giant's entry point to the innovation ecosystem. The firm strategically invests in early-stage transformational science and technology, backing companies at a stage where they are too early to partner with or acquire directly. Its stated mission is to invest in top-tier biotech and digital health companies that focus on helping patients and transforming the practice of medicine. Beyond capital, portfolio companies gain select access to Sanofi's expertise across science, preclinical and clinical development, regulatory affairs, data analytics, manufacturing, market access, and commercialization.
Sector Focus
Sanofi Ventures concentrates on Sanofi's core therapeutic priorities alongside emerging digital and AI-driven health tools:
- Immunology and inflammation
- Rare diseases
- Oncology
- Neurology and neuropsychiatry
- Cell and gene therapy
- Vaccines
- Artificial intelligence and digital health / data science
Stage Focus
The fund invests across all stages of the private company lifecycle, from Seed through Series B and beyond, including selective crossover and growth rounds. It takes pride in staying with portfolio companies through subsequent financings and toward IPO or strategic exit.
Check Size
Exact check sizes are not publicly disclosed. Market data on rounds it has participated in shows an average Series A round size of roughly $57.8M and an average Series B round size of roughly $72.4M across its participations, though Sanofi Ventures' own allocation within those rounds is not broken out.
Lead Tendency
Sanofi Ventures both leads and co-leads financings and participates alongside other investors. Recent examples include co-leading Diagonal Therapeutics' $125M Series B alongside Janus Henderson Investors (January 2026), and participating (non-lead) in BranchLab's $26M Series A led by McKesson Ventures (May 2026) and QuantHealth's strategic investment (October 2025).
Recent Activity
The fund is actively deploying following a September 2025 announcement that Sanofi committed an additional $625 million in fresh capital, bringing Sanofi Ventures' total assets under management to over $1.4 billion. Since its founding in 2012, the fund has deployed more than $800 million across 70+ companies. Recent 2025-2026 activity includes:
- January 2026: Co-led Diagonal Therapeutics' oversubscribed $125M Series B (clustering antibodies for HHT/PAH); Partner Paulina Hill joined the board.
- October 2025: Strategic investment in QuantHealth ($30M total raised), an AI clinical-trial-simulation platform; Partner Cris De Luca joined as board observer.
- May 2026: Participated in BranchLab's $26M Series A (AI platform for pharma commercialization), led by McKesson Ventures.
Portfolio Highlights
Sanofi Ventures' portfolio spans 70+ companies across biotech and digital health, including several public companies (Bluebird Bio, Fate Therapeutics, Fulcrum Therapeutics, GlycoMimetics, Moderna) and a strong recent exit record:
- Curevo Vaccine — agreed to be acquired by Eli Lilly for up to $1.5B (May 2026), advancing a next-generation shingles vaccine.
- Aliada Therapeutics — acquired by AbbVie for $1.4B (announced October 2024, closed December 2024), a blood-brain-barrier-crossing CNS delivery platform.
- Escient Pharmaceuticals — acquired by Incyte (April 2024).
- Icosavax — acquired by AstraZeneca (December 2023).
- Managing Director Jason P. Hafler has noted three realized exits in 2024 alone with a combined acquisition value of $3.25 billion, which the firm points to as validating its evergreen fund structure.
Other active portfolio companies of note include Aetion, Evidation, Epicrispr Biotechnologies, Expedition Therapeutics, AdvanCell Isotopes, Draig Therapeutics, Click Therapeutics, Carbon Health, and Empatica.
Team
- Jason P. Hafler, Managing Director — Joined 2014; formerly Director of Corporate Development at Translate Bio, Associate at Atlas Venture, Flagship Ventures Fellow; PhD, University of Cambridge.
- Laia Crespo, Partner — Joined 2018; formerly Investment Director at Ysios Capital; PhD in Chemistry (University of Barcelona), MBA (Cambridge Judge Business School).
- Cris De Luca, Partner (Digital Health & AI) — Joined 2020; founding member of Johnson & Johnson Innovation (Global Head of Digital Innovation); co-founded Ultra Light Startups.
- Paulina Hill, Partner — Joined 2022; formerly Principal at Omega Funds and Polaris Partners, Founding CEO of CAMP4 Therapeutics; postdoc in Robert Langer's lab at MIT.
- Christopher Gagliardi, Principal — Joined 2017; formerly a management consultant at L.E.K. Consulting; PhD Chemistry (UNC Chapel Hill).
- Meg Krench, Principal — Joined 2021; formerly on the External Innovation team at Vertex Pharmaceuticals and at RA Capital; PhD Neuroscience (MIT).
- Kriti Subramanyam, Director of Investments — Joined 2026; formerly at RA Capital Management's Health Technology and Services team; PhD Medical Engineering and Medical Physics (MIT).
- Francesc Dosrius Lleonart, Associate Director of Investments — Joined 2024; formerly at AdBio Partners and Kiji Therapeutics.
- Pierre Gaudeaux, Associate Director of Investments — Joined 2024; formerly an Analyst at Jeito Capital.
- Rebecca Gorelov, Associate Director of Investments — Joined 2026; formerly at Bain Capital Life Sciences; PhD Harvard University (stem cell biology and epigenetics).
- Steve Bychowski, General Counsel — Joined 2025; at Sanofi since 2020 as legal partner for strategic investments and transactions.
- Anne Jammal, Executive Assistant — Joined 2023; 19 years across multiple Sanofi departments.
Decision Process
As a wholly Sanofi-funded evergreen vehicle, decisions run through an internal investment team of Managing Director, Partners, Principals, and Directors of Investments, consistent with a corporate investment-committee structure. The firm publicly emphasizes speed: "We move quickly, we don't believe in drawn-out processes, and we always aim to provide thoughtful feedback."
Founder Preferences
Sanofi Ventures backs technical and scientific founders building transformational therapeutics platforms and data/AI-driven health tools, often at a stage too early for Sanofi's business development or M&A teams to engage directly. It favors founders solving problems squarely within Sanofi's strategic priorities (immunology, rare disease, oncology, neurology, vaccines) plus digital health and AI applications to drug development and commercialization.
Geographic Focus
Headquartered at 450 Water Street, Cambridge, MA, with a European office at 46-48 Avenue de la Grande Armée, Paris, France. The firm invests primarily in the US and Europe.